secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vir Biotechnology, Inc. (VIR)
CIK:        0001706431
Form:       8-K
Filed at:   2024-08-01T23:59:59+00:00
Accession:  0001628280-24-034143
Event type: earnings
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 2.05, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vir Bio Q2 net loss narrows to $138M; initiates restructuring cutting 25% of workforce
--------------------------------------------------------------------------------

- Net loss of $138.4M ($1.02/sh) vs $194.8M ($1.45/sh) in Q2 2023; cash and investments $1.43B, down $78M in quarter.
- Strategic restructuring reduces workforce by ~140 employees (25%); phases out flu, COVID-19, and T-cell viral vector programs.
- Expects $11–13M in restructuring charges, ~$50M annual workforce cost savings from 2025, and ~$50M program savings through 2025.
- Lowers full-year 2024 GAAP operating expense guidance to $580–610M, excluding Sanofi transaction impact.
- Signed exclusive worldwide license with Sanofi for clinical-stage T-cell engagers; CMO Mark Eisner appointed June 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1706431/000162828024034143/0001628280-24-034143-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1706431/000162828024034143/vir-20240729.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-034143

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer